Annette Clancy, BSc (Hons)

With over 30 years-experience in the Pharmaceutical/Biopharm Industry, Annette Clancy has worked in a variety of functions (R&D, Commercial, Worldwide Business Development) in the US and UK, including 15 years leading the global Transactions team in Business Development at GSK. Since 2009, she has held various positions in public and privately funded healthcare companies and advised Venture Capital Health groups in US and Europe. This experience has provided her with a broad oversight and understanding of the industry. Annette currently serves as the Chair of the Compensation Nomination and Governance Committee at ObsEva SA, is a non-Executive Director on the Board of the Swedish Public Company, Sobi and is Chairperson of the Board of two other Companies; the public French company Lysogene SA and a privately held French company Enyo SA.

Ms. Clancy holds a BSc (Hons) Pharmacology from Bath University (UK) and a series of American Management Association diplomas (finance/marketing).

Leave a Reply

Your email address will not be published. Required fields are marked *

Are you sure you want to leave ObsEva.com?

We’re sorry to see you go. Choose one of the following actions to stay on the site or leave.

Continue to link

Disclaimer

Note that the following information contains information on investigational medicinal products. These products have not yet been approved for marketing by the European Medicines Agency or the U.S. Food and Drug Administration and are still under development. Further additional investigations may be needed in order for the marketing authorization to be granted, which grant may depend on a variety of factors and is not guaranteed. Click on “return” if you do not wish to receive such information. By clicking on “continue” you acknowledge that you wish to receive scientific information on our investigational products.

Continue

Disclaimer

Note that the following information contains information on investigational medicinal products. These products have not yet been approved for marketing by the European Medicines Agency or the U.S. Food and Drug Administration and are still under development. Further additional investigations may be needed in order for the marketing authorization to be granted, which grant may depend on a variety of factors and is not guaranteed. Click on “return” if you do not wish to receive such information. By clicking on “continue” you acknowledge that you wish to receive scientific information on our investigational products.

Continue